

**FORM 51-102F3
MATERIAL CHANGE REPORT**

1. **Name and Address of Company**

ChroMedX Corp. (the “**Company**”)
65 Queen Street West, Suite 520
Toronto, Ontario M5H 2M5

2. **Date of Material Change**

February 2, 2017

3. **News Release**

A press release disclosing the material change was released on February 2, 2017, through the facilities of Newsfile Corp.

4. **Summary of Material Change**

The Company announced that it has closed the second and final tranche of its previously announced non-brokered private placement (the “**Offering**”) by issuing 4,073,667 units (“**Units**”) at a price of \$0.15 per Unit for aggregate gross proceeds of \$611,050.05. Each Unit is comprised of one common share of the Company (a “**Common Share**”) and one Common Share purchase warrant (a “**Warrant**”). Each Warrant entitles the holder thereof to acquire one Common Share at a price of \$0.20 for a period of eighteen (18) months from the closing of the Offering.

5. **Full Description of Material Change**

The material change is fully described in the Company’s press release which is attached as Schedule “A” and is incorporated herein.

6. **Reliance on subsection 7.1(2) of National Instrument 51-102**

The report is not being filed on a confidential basis.

7. **Omitted Information**

No significant facts have been omitted from this Material Change Report.

8. **Executive Officer.**

For further information, contact Ash Kaushal, Chief Executive Officer of the Company at (647) 872-9982.

9. **Date of Report.**

This report is dated at Toronto, this 9th day of February, 2017.

CHROMEDX CORP.

Per: “Ash Kaushal” (Signed)
Ash Kaushal
Chief Executive Officer

SCHEDULE "A"

CHROMEDX CORP.
65 Queen Street West, Suite 520
Toronto, Ontario M5H 2M5

CHROMEDX ANNOUNCES CLOSING OF PRIVATE PLACEMENT

TORONTO, ONTARIO – February 2, 2017 – ChroMedX Corp. (the "**Company**") (CSE: CHX, OTC: MNLIF, Frankfurt: EIY2) is pleased to announce that it has closed the second and final tranche of its previously announced non-brokered private placement (the "**Offering**") by issuing 4,073,667 units ("**Units**") at a price of \$0.15 per Unit for aggregate gross proceeds of \$611,050.05. Each Unit is comprised of one common share of the Company (a "**Common Share**") and one Common Share purchase warrant (a "**Warrant**"). Each Warrant entitles the holder thereof to acquire one Common Share at a price of \$0.20 for a period of eighteen (18) months from the closing of the Offering.

The securities issued in connection with the Offering will be subject to a hold period of four months plus a day from the date of issuance pursuant to applicable securities laws. The proceeds of the Offering will be used for developing prototypes, marketing and general working capital purposes.

Certain eligible persons (the "**Finders**") were paid a cash commission equal to 8% of the proceeds raised from subscribers introduced to the Company by such Finder, and also issued broker warrants (the "**Broker Warrants**") equal to 8% of the securities purchased by such subscribers. Each Broker Warrant entitles the holder thereof to purchase one Common Share at a price of \$0.20 for a period of eighteen (18) months from the closing of the Offering.

About ChroMedX Corp.

ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company's issued and pending patents, dealing with blood collection, analysis and plasma/serum processing.

Contact:

Investor Relations

Office: 647-872-9982 ext. 2

TF: 1-844-247-6633 ext. 2

Email: investor.relations@chromedx.com

Website: www.chromedx.com

Forward-looking Information Cautionary Statement

Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at www.sedar.com.

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.